









## RESEARCH ARTICLE

# Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 1; peer review: awaiting peer review]

Graham S. Cooke <sup>1,2</sup>, Sarah Pett<sup>3-5</sup>, Leanne McCabe <sup>3</sup>, Chris Jones <sup>1,2</sup>, Richard Gilson<sup>4,5</sup>, Sumita Verma<sup>6</sup>, Stephen D. Ryder<sup>7</sup>, Jane D. Collier<sup>8</sup>, Stephen T. Barclay<sup>9</sup>, Aftab Ala<sup>10</sup>, Sanjay Bhagani<sup>11</sup>, Mark Nelson<sup>12</sup>, Chinlye Ch'Ng<sup>13</sup>, Ben Stone<sup>14</sup>, Martin Wiselka<sup>15</sup>, Daniel Forton<sup>16</sup>, Stuart McPherson <sup>17</sup>, Rachel Halford<sup>18</sup>, Dung Nguyen <sup>19</sup>, David Smith <sup>19</sup>, Azim Ansari<sup>19</sup>, Emily Dennis<sup>3</sup>, Fleur Hudson<sup>3</sup>, Eleanor J. Barnes<sup>19,20</sup>, Ann Sarah Walker<sup>3</sup>

<sup>1</sup>Department of Infectious Disease, Imperial College London, London, W2 1NY, UK

<sup>2</sup>NIHR Biomedical Research Centre, Imperial College NHS Trust, London, W2 1NY, UK

<sup>3</sup>MRC Clinical Trials Unit, University College London Medical School, London, UK

<sup>4</sup>Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK

<sup>5</sup>Institute of Global Health, University College London Medical School, London, UK

<sup>6</sup>Hepatology, Brighton and Sussex Medical School, Brighton, UK

<sup>7</sup>Hepatology, Nottingham University Hospitals NHS Trust, Nottingham, UK

<sup>8</sup>Hepatology, John Radcliffe Hospital, Oxford, UK

<sup>9</sup>Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK

<sup>10</sup>Clinical and Experimental Medicine, University of Surrey, Guilford, UK

<sup>11</sup>Infectious Diseases, Royal Free Hampstead NHS Trust Hospital, London, UK

<sup>12</sup>HIV Medicine, Chelsea & Westminster NHS Trust, London, UK

<sup>13</sup>Swansea Bay University Health Board, Swansea, UK

<sup>14</sup>Infectious Diseases, Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, UK

<sup>15</sup>Infectious Diseases, University Hospitals of Leicester NHS Trust, Leicester, UK

<sup>16</sup>Hepatology, St George's Hospital, London, London, UK

<sup>17</sup>Heaptology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle, UK

<sup>18</sup>Hepatitis C Trust, London, UK

<sup>19</sup>Peter Medawar Building for Pathogen Research, Oxford, UK

<sup>20</sup>Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

**V1** First published: 29 Apr 2021, 6:93  
<https://doi.org/10.12688/wellcomeopenres.16594.1>

Latest published: 29 Apr 2021, 6:93  
<https://doi.org/10.12688/wellcomeopenres.16594.1>

## Abstract

**Background:** The world health organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy.

## Open Peer Review

**Reviewer Status** AWAITING PEER REVIEW

Any reports and responses or comments on the article can be found at the end of the article.

**Methods:** A total of 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy (8 weeks) vs variable-duration ultrashort strategies (VUS1/2). Participants not cured following first-line treatment were retreated with 12 weeks' sofosbuvir/ledipasvir/ribavirin. The primary outcome was sustained virological response 12 weeks (SVR12) after first-line treatment and retreatment. Participants were factorially randomised to receive ribavirin with first-line treatment.

**Results:** All evaluable participants achieved SVR12 overall (197/197, 100% [95% CI 98-100]) demonstrating non-inferiority between fixed-duration and variable-duration strategies (difference 0% [95% CI -3.8%, +3.7%], 4% pre-specified non-inferiority margin). First-line SVR12 was 91% [86%-97%] (92/101) for fixed-duration vs 48% [39%-57%] (47/98) for variable-duration, but was significantly higher for VUS2 (72% [56%-87%] (23/32)) than VUS1 (36% [25%-48%] (24/66)). Overall, first-line SVR12 was 72% [65%-78%] (70/101) without ribavirin and 68% [61%-76%] (69/98) with ribavirin (p=0.48). At treatment failure, the emergence of viral resistance was lower with ribavirin (12% [2%-30%] (3/26)) than without (38% [21%-58%] (11/29), p=0.01).

**Conclusions:** Unsuccessful first-line short-course therapy did not compromise retreatment with sofosbuvir/ledipasvir/ribavirin (100% SVR12). SVR12 rates were significantly increased when ultrashort treatment varied between 4-7 weeks rather than 4-6 weeks. Ribavirin significantly reduced resistance emergence in those failing first-line therapy.

**ISRCTN Registration:** 37915093 (11/04/2016).

### Keywords

hepatitis, clinical trial, short course, treatment, ribavirin

**Corresponding author:** Graham S. Cooke ([g.cooke@imperial.ac.uk](mailto:g.cooke@imperial.ac.uk))

**Author roles:** **Cooke GS:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Pett S:** Conceptualization, Formal Analysis, Methodology, Project Administration, Writing – Review & Editing; **McCabe L:** Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Jones C:** Investigation, Project Administration, Writing – Review & Editing; **Gilson R:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Verma S:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Ryder SD:** Data Curation, Project Administration; **Collier JD:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Barclay ST:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Ala A:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Bhagani S:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Nelson M:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Ch'Ng C:** Data Curation, Investigation, Project Administration; **Stone B:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Wiselka M:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Forton D:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **McPherson S:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Halford R:** Data Curation, Investigation, Project Administration; **Nguyen D:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Smith D:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Ansari A:** Data Curation, Formal Analysis, Investigation, Writing – Review & Editing; **Dennis E:** Data Curation, Investigation, Project Administration, Writing – Review & Editing; **Hudson F:** Project Administration, Validation, Writing – Review & Editing; **Barnes EJ:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Review & Editing; **Walker AS:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation

**Competing interests:** GC has received fees from MSD and Gilead unrelated to this work. SR has carried out consultancy work for Gilead SM has received fees from Abbvie, MSD and Gilead unrelated to this work. SLP has received grants from Gilead Sciences and ViiV Healthcare unrelated to this work. DF has received research funding from Gilead and advised and/or spoken for Gilead, Merck and Abbvie unrelated to this work. RG reports grants from abbvie and Gilead unrelated to this work. MN, SMcP and MW report personal fees from MSD, abbvie and Gilead unrelated to this work. SBarclay reports personal fees from abbvie and Gilead unrelated to this work. SBhagani reports personal fees from abbvie, Gilead and MSD. All other authors report no conflicts of interest.

**Grant information:** This work was supported by the Wellcome Trust [206296]. STOP-HCV-1 was funded by the National Institutes of Health Research's Efficacy Mechanism Evaluation programme (Project number 14/02/17). Virological analysis was supported by MRC Stratified Medicine Consortium (MR/K01532X/1 – STOP-HCV Consortium) and core funding to the Wellcome Trust Centre for Human Genetics provided by the Wellcome Trust (090532/Z/09/Z). The MRC Clinical Trials Unit at UCL is supported by funding from the MRC (MC\_UU\_12023/22). ASW is an NIHR Senior Investigator. GC is supported in part by the BRC of Imperial College NHS Trust and is an NIHR Research Professor. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2021 Cooke GS *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Cooke GS, Pett S, McCabe L *et al.* **Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 1; peer review: awaiting peer review]** Wellcome Open Research 2021, 6:93 <https://doi.org/10.12688/wellcomeopenres.16594.1>

**First published:** 29 Apr 2021, 6:93 <https://doi.org/10.12688/wellcomeopenres.16594.1>

## Introduction

The recent and rapid development of treatment for hepatitis C virus (HCV) has enabled an ambitious strategy for the elimination of viral hepatitis as a global public health threat by 2030, with the target of treating 80% of those chronically infected with HCV<sup>1</sup>. Although licensed durations of 8–12 weeks' therapy with directly acting antivirals (DAAs) are significantly shorter, more tolerable and more effective than previous interferon-based therapies<sup>2</sup>, there are patients who still find it challenging to complete a full treatment course. Such patients will become an increasingly important part of clinical practice as treatment coverage expands to reach marginalised groups, and world health organization (WHO) treatment guidelines highlight the need to understand the factors that could be used to select patients for successful short course treatment<sup>3</sup>.

Shorter treatment courses of licensed therapies are likely to improve adherence, including in those with active illicit drug use<sup>4,5</sup>. In acute or recent HCV infection, shortened courses of licensed therapy may have sufficiently high efficacy to be recommended routinely<sup>6</sup>. However, in chronic infection there is limited data to select patients able to achieve high cure rates with short duration therapy. Unselected short duration treatment has been able to achieve cure rates of 20–40% with 4 weeks and 57–95% with 6 weeks treatment in small Phase II studies<sup>7–9</sup>, but few of these combinations or durations were subsequently licensed for use. For licensed therapies, baseline viral load (<6,000,000 IU/mL)<sup>10</sup> and subgenotype<sup>11</sup> have been recommended to shorten therapy from 12 to 8 weeks, but there are no validated criteria to recommend less than 8 weeks therapy in chronic infection.

For a clinician deciding whether to start treatment in a patient considered at high risk of not completing therapy, there is a potential concern that emerging resistance with virological failure may compromise future treatment options. However, it is also possible that with shorter courses of treatment, less resistance may emerge. *In vitro* evidence suggests the addition of ribavirin, a generically available guanosine analogue, may improve rates of virological cure with shorter treatment courses<sup>12</sup> and could reduce the emergence of resistance in those failing treatment when added to short-course therapy<sup>13</sup>. However, these hypotheses have not been tested in a randomised trial.

We performed a strategic post-licensing randomised controlled trial in HCV-infected participants with mild liver disease to evaluate strategies for short-course treatment, the impact of treatment failure on retreatment and the role of adjunctive ribavirin in short-course therapy.

## Methods

### Design

We conducted a multi-centre, randomised, open-label, factorial, parallel group non-inferiority trial of adults with mild chronic HCV in 14 UK centres (Figure 1). The trial was approved by the Cambridgeshire South Research Ethics Committee (15/EE/0435). The trial was registered at ISRCTN (37915093,

11<sup>th</sup> April 2016), and EudraCT (2015-005004-28, 31<sup>st</sup> December 2015). This study is reported in line with the Consolidated Standards of Reporting Trials (CONSORT)<sup>14</sup>.


### Participants

Eligible participants were adults ( $\geq 18$  years) infected with HCV genotype 1a/1b/4 for  $\geq 6$  months, with consistently detectable viremia 6 months before randomisation, no evidence of significant liver fibrosis (Fibroscan score  $\leq 7.1$  kPa equivalent to F0-F1<sup>15</sup>), body mass index (BMI)  $\geq 18$  kg/m<sup>2</sup>, HCV viral load (VL) detectable but <10 million IU/ml at screening, no previous DAA exposure for current infection (previous pegylated-interferon/ribavirin allowed) and with laboratory results meeting minimum thresholds (platelets  $\geq 60 \times 10^9$ /L, haemoglobin >12g/dL (male) or >11g/dL (female), creatinine clearance (estimated using Cockcroft-Gault)  $\geq 60$  ml/min, international normalised ratio (INR) <1.5). Individuals co-infected with HIV were eligible if HIV VL had been <50 copies/ml for >24 weeks on anti-HIV drugs. Participants were excluded if they had a history of malignancy within 5 years, any history of pre-existing cardiac disease or haemoglobinopathies, or a current disorder which may cause ongoing liver disease, may negatively impact the participant's ability to adhere to the study or might limit the participant's life expectancy. Participants were also excluded if they were hypersensitive to any of the study drugs, currently taking any medication known to interact with study medication or had used other investigational products within 60 days of screening. Female participants were excluded if lactating, pregnant, planning to become pregnant or not willing to use effective contraception (excluding products containing ethinyl-oestradiol) including up to four months after the study. Male participants were excluded if they were planning pregnancy with a partner or not willing to use effective contraception for up to seven months after the study. Participants gave written informed consent after explanation of the aims, methods, benefits and potential hazards of the trial and before any trial-specific procedures were performed/any blood taken for the trial.

### Trial setting

Participants were recruited from 14 UK NHS Hospital Trusts: Singleton Hospital, Swansea Bay University Health Board; University Hospitals of Leicester NHS Trust; Imperial College NHS Trust; St George's Healthcare NHS Foundation Trust; Royal Free Hospital NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Royal Surrey County Hospital NHS Foundation Trust; Brighton and Sussex University Hospitals NHS Trust; John Radcliffe Hospital Oxford University Hospitals NHS Foundation Trust; Glasgow Royal Infirmary NHS Greater Glasgow and Clyde; Newcastle Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust; Chelsea and Westminster Hospital NHS Foundation Trust; Central and North West London NHS Foundation Trust; and Sheffield Teaching Hospitals NHS Foundation Trust.

The main criteria for selecting participating hospitals was that they had the potential for recruiting the required number of chronic (>6 months) HCV genotype 1a/1b/4 infected



**Figure 1. Trial schematic.** Note: DAA: direct-acting antivirals. The ribavirin randomisation was a partial factorial in those randomised to a shorter course than the full licensed duration of therapy (the vast majority of participants recruited to the trial).

participants within the agreed recruitment period. This was established by the use of a trial specific site survey. Site also needed to meet the following criteria: no competing studies that would impact on the ability to enrol quickly to the trial; turnaround of no more than 7 days for HCV viral load test results; ability to provide 24 hour cover for trial patients; local governance approval likely to take <3 months.

### Randomisation

Participants were randomised 1:1 to variable ultrashort-course treatment strategy (VUS) or fixed 56 days of first-line treatment. Individuals were also randomised 1:1 using a factorial design to adjunctive ribavirin or no ribavirin with first-line therapy. Randomisation determined duration of first-line therapy rather than choice of DAAs which was pre-specified by the investigator before randomisation based on local availability from (i) [genotype 1a/1b] co-formulated

ombitasvir/paritaprevir/ritonavir once daily plus separate dasabuvir once-daily (total 25mg/150mg/100 mg plus 500mg, respectively) (ii) [genotype 4] ombitasvir/paritaprevir/ritonavir 25/150/100mg once-daily (iii) [genotype 1a/1b/4] glecaprevir/pibrentasvir 300/120mg once-daily (only available after 1 November 2017). Ribavirin dosing was weight-based twice-daily (<75kg 1000mg/day, ≥75kg 1200mg/day). All drugs were taken orally.

### Intervention and procedures

For participants allocated to VUS, the duration of first-line therapy varied between 28 and 42 (mean 32; before 1 April 2017) or 49 (mean 39; after 1 April 2017) days determined by the baseline screening VL using a continuous scale (Table 1, Table 2, Figure 2). Blinding was not used because the primary end-point was an objective measure of viraemia blinded to clinical data measured in routine laboratories without knowledge of randomisation.

**Table 1. Duration of first-line treatment in the variable-duration group by protocol version.**

From HCV VL (IU/ml)	To HCV VL (IU/ml)	Days if randomised before 01/04/2017 (VUS1)	Days if randomised after 01/04/2017 (VUS2)
LLOQ	50,000	28	28
50,001	65,000	28	29
65,001	82,500	28	30
82,501	110,000	28	31
100,001	140,000	28	32
150,001	180,000	28	33
175,001	235,000	28	34
225,001	300,000	28	35
300,001	400,000	29	36
400,001	500,000	30	37
500,001	550,000	30	38
550,001	650,000	31	38
650,001	750,000	31	39
750,001	850,000	32	39
850,001	1,100,000	32	40
1,100,001	1,300,000	33	41
1,300,001	1,450,000	34	41
1,450,001	1,700,000	34	42
1,700,001	1,850,000	35	42
1,850,001	2,200,000	35	43
2,200,001	2,400,000	36	43
2,400,001	2,850,000	36	44
2,850,001	3,150,000	37	44
3,150,001	3,600,000	37	45
3,600,001	4,100,000	38	45
4,050,001	4,550,000	38	46
4,550,001	5,250,000	39	46
5,250,001	5,700,000	39	47
5,700,001	6,800,000	40	47
6,800,001	7,100,000	40	48
7,100,001	8,800,000	41	48
8,800,001	upwards	42	49

Note: VUS: variable ultra-short

All patients failing treatment were retreated as soon as practicable with 12 weeks of oral sofosbuvir 400mg/ledipasvir 90mg once-daily and weight-based oral ribavirin twice-daily (dosing as above). Treatment failure was defined as (i) two consecutive measurements of HCV VL above the lower limit of quantification (LLOQ) (taken at least one week apart) after two consecutive visits with HCV VL <LLOQ at any time, with the latter confirmatory measurement also being >2000 IU/mL, or (ii) two consecutive measurements of HCV VL (taken at least one week apart) that were >1log<sub>10</sub> increase above the nadir on treatment and >2000 IU/mL at any time.

All participants were followed by the site teams for 24 weeks after the end of first-line treatment or re-treatment (where

applicable) for evaluation of virological response and toxicity. Participants on first-line therapy had clinical assessments on days 3, 7, 10, 14, 28 and end of treatment (EOT, where EOT was not day-28) followed by weeks 2, 4, 8, 12 and 24 after EOT. All outcome measures were assessed at these clinic visits.


**Randomisation**

Randomisation was performed via a computer-generated programme at the STOP-HCV-1 Co-ordinating Centre (MRC CTU at UCL). Patients were allocated 1:1 using a factorial design to each of: biomarker-stratified variable ultrashort vs fixed duration; adjunctive ribavirin or not (a partial factorial in those randomised to a shorter course than the full licensed duration of therapy). Randomisation was stratified by study centre, HCV genotype and study drug regimen using a minimisation algorithm incorporating a probabilistic element incorporated securely into the online trial database. Randomisation determined the duration of first-line therapy rather than the choice of DAAs which was pre-specified by the investigator before randomisation based on local availability.

Each allocation was generated within the trial database only at the point of randomisation after it was confirmed the participant was eligible and was to be randomised. Allocations were generated using minimisation with a probabilistic element, so there was no pre-determined allocation sequence to conceal. To further conceal the potential allocation, study centres were not informed of the randomisation strata.

**Table 2. Summary of length of treatment received in the variable duration arm.**

	VUS1 N=68	VUS2 N=34	Total N=102
4-5 weeks (28-34 days)	48 (71%)	11 (32%)	59 (58%)
5-6 weeks (35-42 days)	18 (26%)	13 (38%)	31 (30%)
6-7 weeks (42-49 days)	2 (3%)	10 (29%)	12 (12%)
Mean (SD)	32 (4.2)	39 (5.6)	35 (5.7)



**Figure 2. Duration of first-line treatment in the variable-duration group.** DAA: direct acting antivirals; VUS1: variable ultra-short 1 (4-6 weeks); VUS2: variable ultra-short (4-7 weeks). Note: Lines represent protocol determined treatment duration according to screening viral load (x axis).

On the day of randomisation, participant eligibility was checked at sites and the data confirming eligibility was entered onto a case record form and sent to MRC CTU. The data was entered onto the database at MRC CTU and checked for eligibility again. Once confirmed that the participant was eligible, the database would perform randomisation using the computer-generated programme. Sites were then informed of the allocation and length of DAA treatment required for the participant.

### Sample size

A *a priori* power calculation assumed 88% of participants would achieve SVR12 on first-line fixed-duration, and that SVR12 would be 85% on retreatment (significantly lower than the actual retreatment success rate, below), leading to an overall cure rate of 98% (first-line plus retreatment) in the control group. Assuming 98% cure rate in the fixed-duration group, 80% power, one-sided alpha 0.025, and a 5% loss to follow-up, 408 participants were needed to demonstrate non-inferiority with a 4% margin. The choice of the 4% margin was based on clinical judgement and to ensure that overall cure rates in the variable-duration group would be well over 90% if non-inferiority was demonstrated. Interim data were reviewed by an independent Data Monitoring Committee (DMC) (4 biannual meetings). The protocol stipulated that the DMC could alter the first-line treatment strategy if there was strong evidence the SVR12 rate for VUS1 was less than 65%. After the DMC meeting in April 2017, the DAA duration strategy was changed from 4–6 weeks (VUS1) to 4–7 weeks (VUS2) (Table 1). All participants randomised from the 1st April 2017 were treated under VUS2. The trial closed in August 2018 when no further recruitment was possible. By this time, the great majority of patients with viraemia were unable to engage with treatment *per se*, and not suitable for inclusion in this study.

### Outcomes

The primary outcome was sustained virological response 12 (SVR12, plasma HCV VL <LLOQ without prior failure 12 weeks after the end of the combined first and any re-treatment phases). For ribavirin comparison the primary outcome was SVR12 after first-line treatment only. Secondary outcomes were SVR12 after first-line treatment (where not the primary outcome), SVR12 after the end of the combined first and any re-treatment phases (where not the primary outcome), SVR24 (24 weeks) after the end of the combined first and any re-treatment phases, SVR24 after first-line treatment only, lack of initial virological response, viral load rebound after becoming undetectable, serious adverse events, grade 3/4 adverse events, grade 3/4 adverse events judged definitely/probably related to interventions, treatment-modifying adverse events (any grade), grade 3/4 anaemia and emergence of resistance-associated HCV variants. Adverse events were graded following the Division of AIDS grading tables. Full genome sequence was obtained by RNA Sequencing on Illumina Miseq platform following target enrichment with a library of genotype specific HCV capture probes as described previously<sup>16</sup>.

### Statistical analysis

Randomised groups were compared following the principle of intention-to-treat (including all follow-up regardless of changes to treatment) using binomial regression (risk difference scale) to estimate risk differences for binary outcomes, Kaplan-Meier and Cox regression for time to first-line failure (with competing risks methods for its components, primary failure and VL rebound), and generalised estimating equations with independent working correlation for global tests of repeated measures (adjusted for baseline for continuous measures). A per-protocol analysis included patients receiving >90% and <100% of the prescribed duration of first-line treatment and where the difference between screening and enrolment HCV RNA values would have led to a difference of  $\leq 2$  days in allocated duration of DAAs had they been allocated to the variable-duration group. Primary analyses of outcomes restricted to first-line therapy were stratified by first-line DAA strategy in place (VUS1 (before 1 April 2017) or VUS2 (after 1 April 2017)) as a main effect, and as an interaction with randomised group (fixed-duration vs variable-duration), where the p-value for the interaction term was <0.05. Primary analyses of outcomes including retreatment were unstratified, reflecting the overall strategy comparison and because no patients failed after receiving retreatment. Analyses used *Stata* v15.1. No adjustment was made for multiple testing. All subgroups within the subgroup analyses were pre-specified in the protocol. Further information on statistical methods and results can be found as extended data<sup>17</sup>.

### Results

Between 18 March 2016 and 28 August 2018, 204 participants from 14 UK centres were randomised (Figure 3). Two participants were randomised in error and excluded, leaving 202 (102 fixed-duration, 100 variable-duration; 100 ribavirin, 102 no-ribavirin) participants in the analyses<sup>18</sup>.

Baseline characteristics were broadly balanced between randomised groups (Table 3) and across strategies (before vs after 1 April 2017). Median screening and enrolment HCV VL were 711423 and 741946 IU/mL in samples taken a median (IQR) 19 (13,33) days apart. Whilst the median (IQR) difference was 0.01 (-0.19,+0.21)  $\log_{10}$  IU/mL, absolute differences were greater (Figure 4), leading to 57 (28%) participants being excluded from the per-protocol analysis because they would have received a difference of  $\geq 3$  days of DAAs had this been determined by the enrolment rather than the screening VL (31 (23%) VUS1 vs 26 (39%) VUS2, because the second strategy received more drug overall).

### Follow-up and treatment received

Each pre- or post- first-line EOT visit was missed by no more than eight (4%) participants. One participant was lost-to-follow-up at day-28 on first-line and three (all randomised to fixed-duration, two with ribavirin) stopped first-line treatment >1 week early. All other participants completed first-line treatment (Figure 5). Adverse events caused one participant to stop both first-line DAAs and ribavirin three days early





**Figure 3. Trial profile.** Note: EOT+12: 12 weeks after the end of treatment; EOT+24 24 weeks after the end of treatment. Some patients lost to follow up are included in the analysis based on local VLs from clinics.

**Table 3. Characteristics at randomisation.**

	Total (N=202)	VUS duration (N=100)	Fixed duration (N=102)	Ribavirin (N=100)	No ribavirin (N=102)
Randomised under first protocol (VUS1)	136 (67%)	68 (68%)	68 (67%)	68 (68%)	68 (67%)
Age (years)	45.5 (37.5, 53.0)	45.2 (38.8, 51.6)	46.3 (36.6, 54.1)	46.1 (36.7, 52.4)	44.8 (37.7, 54.1)
Female at birth	62 (31%)	28 (28%)	34 (33%)	34 (34%)	28 (27%)
BMI (kg/m <sup>2</sup> )	24.9 (22.2, 27.2)	24.9 (22.6, 26.7)	24.9 (21.8, 27.7)	23.7 (21.7, 26.5)	25.8 (23.3, 27.6)
White ethnicity	176 (87%)	89 (89%)	87 (85%)	89 (89%)	87 (85%)
Weight (kg)	74.0 (66.0, 84.6)	73.0 (65.9, 84.1)	76.1 (66.0, 85.9)	69.9 (63.8, 82.3)	78.9 (68.5, 86.8)
Screening HCV viral load (IU/ml)	711423 (218776,1995262)	790664 (214388, 1917731)	687916 (220000, 2381846)	700272 (169717, 2071064)	750523 (275000, 1949844)
Enrolment HCV viral load (IU/ml) n=199	741946 (249097,1872136)	801000 (251188, 1500000)	(614047 (248000, 2238721)	657858 (178842, 1500000)	801000 (385595, 2200000)
HCV genotype/subgenotype: 1a	166 (82%)	82 (82%)	84 (82%)	84 (84%)	82 (80%)
1b	34 (17%)	17 (17%)	17 (17%)	16 (16%)	18 (18%)
4	2 (1%)	1 (1%)	1 (1%)	0	2 (2%)
HIV coinfectd	68 (34%)	32 (32%)	36 (35%)	35 (35%)	33 (32%)
Fibrosan result (kPa)	4.9 (4.2, 5.8)	5.0 (4.3, 5.9)	4.8 (4.1, 5.5)	4.8 (4.4, 5.8)	4.9 (4.1, 5.9)
Haemoglobin (g/dl)	14.7 (14.0, 15.6)	14.8 (14.1, 15.6)	14.7 (13.8, 15.6)	14.7 (13.8, 15.6)	14.8 (14.0, 15.7)
ALT (IU/ml)	52 (34, 87)	50 (34, 90)	54 (34, 87)	51 (35, 89)	54 (31, 87)
AST (IU/l) n=189	38 (30, 57)	38 (29, 57)	38 (31, 58)	39 (31, 55)	38 (29, 58)
ALP (IU/l)	72 (59, 91)	71 (59, 87)	75 (59, 94)	76 (61, 95)	69 (58, 85)
eGFR (ml/min)	109 (93, 131)	109 (94, 126)	109 (92, 138)	107 (92, 126)	110 (93, 133)
Total bilirubin (umol/l)	9 ( 6, 12)	8 (6, 11)	9 (6, 12)	9 (6, 12)	9 (6, 12)
IL28b genotype*: CC	60 (30%)	32 (32%)	28 (27%)	29 (29%)	31 (30%)
CT	106 (52%)	51 (51%)	55 (54%)	56 (56%)	50 (49%)
TT	27 (13%)	14 (14%)	13 (13%)	11 (11%)	16 (16%)
No result	9 (4%)	3 (3%)	6 (6%)	4 (4%)	5 (5%)
Previously unsuccessfully treated with interferon and/or ribavirin	24 (12%)	12 (12%)	12 (12%)	11 (11%)	13 (13%)
Ever spontaneously cleared and re-infected	6 (3%)	4 (4%)	2 (2%)	2 (2%)	4 (4%)
Ever successfully treated with interferon and/or ribavirin and re-infected	10 (5%)	5 (5%)	5 (5%)	5 (5%)	5 (5%)
Current/recent alcoholism/alcohol abuse	13 (6%)	5 (5%)	8 (8%)	7 (7%)	6 (6%)
Current/recent illicit substance abuse	64 (32%)	31 (31%)	33 (32%)	28 (28%)	26 (25%)
Treated with paritaprevir\ombitasvir\ dasabuvir	198 (98%)	98 (98%)	100 (98%)	100 (100%)	98 (96%)
Treated with paritaprevir\ombitasvir	2 (1%)	1 (1%)	1 (1%)	0	2 (2%)
Treated with glecaprevir\pibrentasvir	2 (1%)	1 (1%)	1 (1%)	0	2 (2%)

\* Result from whole genome sequencing or from Epistem point of care test if genotyping result not available.

Note: showing n (%) for categorical factors, or median (IQR) for continuous factors. Missing data indicated by denominators in the row label. As an indicator of imbalance, P>0.05 for all comparisons of baseline characteristics between groups other than BMI (p<0.001), weight (p=0.003) and ALP (p=0.04) between ribavirin and no ribavirin groups.




Figure 4. HCV VL at screening and enrolment by assay.




Figure 5. Self-reported treatment duration and first-line SVR24. Note: Lines represent protocol determined treatment duration according to screening viral load (x axis). Symbols represent self-reported individual duration of therapy. Patients could stop DAAs early for adverse events or personal reasons, and take DAAs for longer than prescribed if any missed doses were taken at the end of treatment. Excludes one patient lost-to-follow-up during first-line whose outcome on first-line is unknown.

(grade 3 mouth sores), and one ribavirin only two days early (grade 3 anaemia). Self-reported non-adherence to DAAs and/or ribavirin varied from 2–14% across first-line visits (Figure 6(a)), with 55 (28%) reported missing doses at any first-line visit (40 (20%) at one visit only). Each retreatment visit was missed by at most four (6%) participants, with the exception of week-8 post-retreatment (missed by 10 (16%) participants). Self-reported non-adherence was substantially higher on retreatment (Figure 6(b)), 12–19% across visits, 24 (39%) at any retreatment visit, 17 (27%) at one retreatment visit only).

### Sustained virological response (SVR)

One participant withdrew consent (retreatment week-4) and a further 13 (6%) participants were lost-to-follow-up (1 on first-line, 9 post first-line EOT, 2 on retreatment, 1 post retreatment EOT; total withdrawn/lost 9 (9%) fixed-duration, 4 (4%) variable duration). However, HCV VL results were available from medical notes for most of those not withdrawing consent, meaning first-line SVR12 and SVR24 could not be ascertained for only 3 (1%) and 6 (3%) participants, respectively (1/2 and 3/3 fixed/variable-duration, respectively), and overall (first-line plus retreatment) SVR12 and SVR24 for only 5 (2%) and 8 (4%) participants (2/3 and 4/4 fixed/variable-duration) respectively.

Overall, all evaluable participants achieved SVR12 (and SVR24) on first-line plus retreatment (primary outcome for fixed vs variable-duration randomisation) (100% (95%CI 96%,100%) in both groups, difference 0% (95%CI (Newcombe) -3.8%,+3.7%), within the pre-specified 4% non-inferiority margin).

First-line SVR12 (secondary outcome) was 91% (95% CI 86%,97%; 92/101) in the fixed-duration group vs 48% (39,57%; 47/98) in the variable-duration group (Figure 7(a); difference -43% (95% CI -54%,-32%),  $p<0.0001$ ). However, SVR12 was significantly higher for VUS2 (72% (56%,87%); 23/32) than VUS1 (36% (25%,48%); 24/66) (interaction between duration randomisation and strategy  $p=0.001$ ). First-line SVR12 was 72% (65%,78%); 70/101) with ribavirin and 68% (61%,76%; 69/98) without (difference -3% (-13%, +6%)  $p=0.48$  adjusting for interaction between duration randomisation and strategy). There was no evidence of interaction between ribavirin and duration randomisations overall (heterogeneity  $p=0.16$  adjusted for the interaction between duration randomisation and strategy) or in the variable-duration group, where SVR12 was 52% (37%,67%; 25/48) with ribavirin vs 44% (30%,59%; 22/50) without ribavirin (difference 8% (95% CI -10%,+27%),  $p=0.38$ ).

The difference in first-line SVR12 between fixed-duration vs variable-duration was significantly smaller in 2 of 16 subgroups pre-specified in the protocol, suppression at day-7 or day-14 (heterogeneity  $p=0.02$ , 0.03 respectively) (Figure 7(b) and Figure 8). Considering the time when individuals first became undetectable, all 10 individuals who became undetectable at day-3 of treatment achieved first-line SVR12 regardless of treatment duration (as did 31/38 (82%) of those first

undetectable at day-7) (Figure 7(c)). In the ribavirin randomisation, no subgroup had a difference that was significantly larger or smaller (Figure 9).


In total, 70 (70%) receiving VUS1/VUS2 vs 72 (71%) receiving fixed-duration were included in the per-protocol population and 68 (68%) receiving ribavirin vs 74 (73%) not receiving ribavirin (received >90% and <100% of the prescribed duration of first-line treatment and had a difference between screening and enrolment HCV RNA values leading to a difference of  $\leq 2$  days in allocated duration of DAAs had they been allocated to the variable-duration group). For the duration randomisation SVR12, after first-line and any retreatment was 100% overall (95% CI 97%, 100%) with a difference of 0% (95% CI (Newcombe) -5%, +5%). SVR12 after first-line only was 47% (95% CI 36%, 59%; 32/69) in the variable-duration group vs 93% (95% CI 87%, 99%; 66/71) in the fixed-duration group. The difference was -46% (95% CI -59%, -33%;  $p<0.0001$ ). For the ribavirin randomisation, SVR12 after first-line and any retreatment was 100% overall (95% CI 97%, 100%) with a difference of 0% (95% CI (Newcombe) -0.06%, +0.05%). SVR12 after first-line only was 70% (95% CI 61%, 78%; 48/66) in the ribavirin group vs 70% (95% CI 62%, 78%; 50/74) in the no ribavirin group. The difference was -0% (95% CI -11%, +10%;  $p=0.93$ ).

Results were similar for SVR24. For the duration randomisation, SVR24 after first-line and any retreatment was 100% overall (95% CI 98%, 100%; 194/194) with a difference of 0% (95% CI (Newcombe) -3.8%, +3.8%). SVR24 after first-line only was 47% (95% CI 38%, 56%; 46/97) in the variable-duration group vs 89% (95% CI 83%, 95%; 88/99) in the fixed-duration group. The difference was -42% (95% CI -53%, -31%;  $p<0.0001$ ). For the ribavirin randomisation, SVR24 after first-line and any retreatment was 100% overall (95% CI 95%, 100%; 194/194) with a difference of 0% (95% CI (Newcombe) -3.8%, 3.8%). SVR24 after first-line only was 69% (95% CI 61%, 76%; 68/97) in the ribavirin group vs 68% (95% CI 60%, 76%; 66/99) in the no ribavirin group. The difference was 1% (95% CI -9%, +11%;  $p=0.87$ ).

### Timing of failure

Only 1 (0.5%) (VUS1) participant failed on treatment (at EOT, 28 days DAAs). 21 (10%) participants had primary first-line failure (VL never confirmed undetectable) (5 (5%) fixed-duration vs 16 (16%) variable-duration,  $p=0.008$ , Figure 10(a)); in the variable-duration group, primary failure occurred in 16 (24%) VUS1 vs 0 (0%) VUS2 ( $p=0.002$ ; interaction not estimable across strategies). 41 (20%) participants had VL rebound after confirmed undetectable HCV VL (6 (6%) fixed-duration vs 35 (35%) variable-duration,  $p<0.0001$ , Figure 10(b); 26 (38%) VUS1, 9 (28%) VUS2, heterogeneity  $p=0.60$ ). There was no evidence that ribavirin was associated with primary failure ( $p=0.83$ ) or rebound ( $p=0.59$ ) (Figure 11). Failure tended to occur earlier with VUS1 vs VUS2 ( $p=0.08$ ), and with variable-duration vs fixed-duration ( $p=0.07$ ; VUS1 vs fixed-duration  $p=0.03$ ). However, there was no evidence of differences in failure VLs (median 158073

(a) First-line treatment



(b) Retreatment






Figure 6. Reported missing doses by ribavirin randomisation. (a) First-line treatment. (b) Retreatment.


(a) overall SVR12, and first-line SVR12 by randomised groups and strategy (VUS1/VUS2)




(b) variation in the difference between fixed-duration vs variable-duration in first-line SVR12 by key subgroups for fixed-duration vs varying duration




(c) first-line SVR12 by time first suppressed



**Figure 7. SVR12.** (a) overall SVR12, and first-line SVR12 by randomised groups and strategies (VUS1/VUS2). (b) variation in the difference between fixed-duration vs variable-duration in first-line SVR12 by key subgroups. (c) first-line SVR12 by time first suppressed. Note: FL=first-line, RT=retreatment. Fixed = overall SVR12 for 8 week therapy. Fixed1=fixed duration when VUS duration received VUS1, Fixed2=fixed duration when VUS duration received VUS2. In panel (b), solid bars represent the first subgroup (detectable VL at the various days shown, no previous unsuccessful treatment, no baseline resistance to drugs taken first-line) and empty bars the second subgroup (undetectable VL at the various days shown, previous unsuccessful treatment, baseline resistance to drugs taken first-line). p-values are heterogeneity p-values comparing the difference between fixed vs VUS1/VUS2 strategies across the two subgroups. Heterogeneity p-value for D3 VL cannot be estimated due to perfect prediction. Panel (c) does not include 8 patients who never had VL suppression; for patients allocated 28–31 days, their EOT visit is also their 28 day visit and they are included in each group.




**Figure 8. Subgroup analyses for first-line SVR12 by fixed-duration vs variable-duration randomisation.** Note: RAS=resistance associated substitution. All heterogeneity tests also adjusted for the interaction between strategy and fixed-duration vs variable-duration randomisation. Some confidence intervals and heterogeneity p-values could not be estimated due to perfect prediction.




**Figure 9. Subgroup analyses for first-line SVR12 by ribavirin randomisation.** Note: RAS=resistance associated substitution. All heterogeneity tests also adjusted for the interaction between strategy and fixed-duration vs variable-duration randomisation. Some confidence intervals and heterogeneity p-values could not be estimated due to perfect prediction. All participants with genotype 4 did not receive ribavirin so not included.



**(a) Primary first-line failure (never confirmed detectable)**




**(b) HCV VL rebound (after confirmed detectable)**




**Figure 10. Time to failure on first-line by fixed duration vs variable duration randomisation. (a) Primary first-line failure (never confirmed detectable). (b) HCV VL rebound (after confirmed detectable).**

**(a) Primary first-line failure (never confirmed undetectable)**



**(b) HCV VL rebound (after confirmed undetectable)**



**Figure 11. Time to failure on first-line by ribavirin randomisation. (a) Primary first-line failure (never confirmed detectable). (b) HCV VL rebound (after confirmed detectable).**

(VUS1), 89125 (VUS2), 346737 (fixed-duration),  $p(\text{VUS2 vs VUS1})=0.41$ ,  $p(\text{VUS2 vs fixed-duration})=0.21$ ). All participants who met failure criteria on first-line started retreatment, a median (IQR) 2.9 (2.0,4.4) weeks after failure was confirmed.

Corresponding to the timing of failures, the percentages with undetectable VL decreased more rapidly post-EOT in VUS1 vs VUS2 ( $p<0.0001$ ) or VUS1 vs fixed-duration ( $p<0.0001$ ) (Figure 12(a)). There was no evidence of differences in the proportions with detectable VL at EOT in VUS1 compared to VUS2 ( $p=0.33$ ) or fixed-duration ( $p=1.00$ ). There was no evidence that ribavirin was associated with higher percentages detectable post-EOT overall ( $p=0.48$ ) or, within the variable-group, between VUS1 vs VUS2 (interaction  $p=0.17$ , Figure 12(b)).

### Emergence of resistance

In total, 14 participants who failed on first-line treatment developed a new resistance mutation (not present at baseline) to at least one of their prescribed drugs (Table 4, Table 5). Within paired samples available at baseline and failure, there was no evidence of a difference in emergent resistance between fixed-duration and variable-duration (3/10 (30%) vs 11/46 (24%), respectively,  $p=0.77$ ). However, ribavirin was associated with lower emergence of resistance to first-line drugs (3/27 (11%) with vs 11/29 (38%) without ribavirin,  $p=0.01$ ; Figure 13) with significantly lower rates of resistance to any DAA and to NS5a inhibitors (both  $p=0.01$ ).

### Adverse events

Overall, five (5%) variable-duration vs five (5%) fixed-duration participants experienced serious adverse events (SAEs) (hazard ratio (HR)=0.77 (95% CI 0.21,2.80)  $p=0.69$ ) and nine (9%) vs five (5%) respectively experienced Grade 3/4 adverse events (AEs) (HR=1.74 (0.58,5.24)  $p=0.33$ ) (Table 6, Table 7). Similarly, five (5%) ribavirin vs five (5%) no ribavirin participants experienced SAEs (HR=1.05 (95% CI 0.30,3.63)  $p=0.59$ ) and nine (9%) vs five (5%) respectively experienced Grade 3/4 AEs (HR=1.92 (0.64,5.72)  $p=0.59$ ) (Table 7, Table 8). Treatment-related AEs, AEs causing changes to treatment and Grade 3/4 anaemia were all uncommon (Table 6); all Grade 3/4 anaemias occurred in participants randomised to adjunctive ribavirin ( $p=0.12$ ) as did all first-line drug changes for AEs ( $p=0.06$ ) (Table 8).

### Discussion

This large strategic post licensing trial demonstrated overall non-inferiority of strategies using first-line ultrashort treatment durations, with both variable duration and fixed duration groups achieving 100% SVR12 rate after retreatment. The initial shortening strategy (VUS1) was able to cure only 36% of participants first-line but, strikingly, a relatively small increase in ultrashort treatment duration (from a mean of 32 days to 39 days) resulted in a doubling of SVR12 rates (from 36% to 72%). The 8-week fixed-duration strategy, with an SVR12 of 91%, did not have higher efficacy than previous phase II trials of shorter treatment courses<sup>19</sup>, despite limiting the maximal baseline viral load in those enrolled, which might have been expected to reduce the risk of failure. The trial's findings

suggest a high proportion of patients can be cured with, on average, approximately 60% of the licensed duration of first-line therapy with the agents used in the trial (VUS2 strategy). However, first-line cure rates were not sufficient to be routinely recommended for stable patients able to adhere to 8–12 weeks' therapy.


Previous work has found adherence to DAA therapy declines as treatment progresses, with patients citing "feeling as if the treatment is working" as a reason for decreasing adherence<sup>5</sup>. Despite trial participants generally being considered to have better adherence, we found similarly decreasing adherence with time on first-line, with 28% reporting missed first-line doses, and poorer adherence to retreatment (despite its 100% SVR12) (Figure 5). That we observed 72% SVR12 with VUS2 (mean duration 39 days) despite 28% reporting missing doses, suggests that intermittent non-adherence may be less important than overall adherence during weeks 4 to 8 of first-line treatment, and emphasise the importance of supporting adherence after week 4 of therapy to ensure good cure rates in hard-to-reach populations<sup>10,20</sup>.

The risk of virological failure, in a patient unlikely to complete the recommended treatment course, is a clinical concern. Emergent resistance could compromise retreatment, particularly where retreatment does not include a protease inhibitor (as in this trial, in contrast to licensed retreatment options). This is also an ethical consideration in short-course therapy trials. We found the first-line treatment strategy did not compromise participants' ability to ultimately achieve SVR12. Whether this would be the case with pan-genotypic first-line treatment regimens remains to be tested, although it seems plausible. The 100% SV12 rates for retreatment is reassuring from an ethical perspective and suggests that, in certain circumstances, the combination may represent a viable retreatment option for patients failing therapy where access to licensed retreatment options (such as sofosbuvir/velpatasvir/voxilaprevir) remains limited.


Although ribavirin side-effects, particularly anaemia and fatigue, increasingly limit its use<sup>2,12</sup> it still has a role for some patients<sup>13</sup> with limited evidence that it can increase efficacy<sup>21</sup> and *in vitro* evidence that it may reduce the emergence of resistance with short course therapy<sup>22</sup>. Here, additional ribavirin was well tolerated, with only 2–4% participants experiencing adverse events. Across randomised groups, there was no evidence of improvement in SVR12. However, the emergence of resistance was significantly lower in those failing therapy (12% with ribavirin v 38% without), the first time this has been demonstrated in a randomised trial. This suggests that adjunctive ribavirin may have a role for some patients considered at high risk of not completing therapy in order to reduce the risk of compromising retreatment and further work is required to understand better the mechanism of action in this setting.

Response-guided therapy, shortening treatment based on initial virological response, was commonplace for interferon-based therapy<sup>23</sup> but this approach is not currently recommended

**(a) By duration randomisation**



**(b) By duration randomisation**




**Figure 12. HCV VL suppression first-line.** (a) By duration randomisation. Note: EOT=end of treatment. Carrying forward last detectable value for participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were receiving DAAs (global  $p=0.13$  comparing fixed-duration vs variable-duration combined;  $p=0.10$  and  $0.82$  comparing VUS1 and VUS2 vs fixed, respectively). Post-EOT global  $p<0.0001$  comparing fixed-duration vs variable-duration vs variable-duration combined;  $p<0.0001$  and  $0.53$  comparing VUS1 and VUS2 vs fixed, respectively. (b) By ribavirin randomisation. Note: EOT=end of treatment. Carrying forward last detectable value for participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were receiving DAAs (global  $p=0.62$  comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined); interaction  $p=0.28$ ). Post-EOT global  $p=0.48$  comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined; interaction  $p=0.22$ ).

**Table 4. Summary of RAS to any DAA in genotype 1a by time point.**

	Baseline	Post-failure
Resistance to NS5a inhibitors	N=13	N=18
24: K24R	1 (8%)	2 (11%)
28: M28T	-	5 (28%)
M28V	6 (46%)	5 (28%)
30: Q30H	1 (8%)	-
Q30L	-	1 (6%)
Q30R	-	6 (33%)
31: L31M	-	2 (11%)
58: H58D	-	2 (11%)
93: Y93F	1 (8%)	-
Y93H	-	1 (6%)
Y93N	1 (8%)	1 (6%)
Resistance to NS5b inhibitors	N=7	N=3
448: Y448H	2 (29%)	-
556: S556G	5 (71%)	3 (100%)
Resistance to protease inhibitors	N=30	N=14
36: V36M	1 (3%)	1 (7%)
55: V55A	3 (10%)	2 (14%)
V55I	3 (10%)	1 (7%)
80: Q80K	21 (70%)	9 (64%)
Q80L	1 (3%)	-
155: R155K	-	1 (7%)
168: D168A	-	1 (7%)

**Table 5. Summary of RAS to any DAA genotype in 1b by time point.**

	Baseline	Post failure
Resistance to NS5a inhibitors	N=13	N=2
30: R30Q	1 (8%)	-
31: L31I	1 (8%)	-
L31M	1 (8%)	-
37: L37I	1 (8%)	-
54: Q54H	11 (84%)	2 (100%)
58: P58S	1 (8%)	-
Resistance to NS5b inhibitors	N=10	N=3
159: L159F	5 (50%)	1 (33%)
316: C316H	2 (20%)	1 (33%)
C316N	4 (40%)	1 (33%)
556: S556G	6 (60%)	3 (100%)
Resistance to protease inhibitors	N=2	N=1
122: S122N	1 (50%)	1 (100%)
168: D168E	1 (50%)	-



**Figure 13. Resistance at baseline (all tested participants) and at first-line failure (failures only).** Note: DAA: direct acting antivirals. p-values are comparing any resistance, to first-line drug or any other DAA, between ribavirin groups. Coloured bars represent resistance to drugs received first-line, white bars, all DAAs including those not used in the trial.

**Table 6. Summary of adverse events by fixed duration vs variable duration randomisation.**

	Variable-duration	Fixed-duration	Total	p-value*
Number randomised	N=100	N=102	N=202	
Median weeks follow-up (IQR)	49.0 (29.0, 54.4)	32.0 (32.0, 33.0)	32.1 (31.2, 50.4)	
<b>SAEs</b>	<b>5 (5%) [5]</b>	<b>5 (5%) [5]</b>	<b>10 (5%) [10]</b>	<b>p=1.00</b>
Life-threatening	1 (1%) [1]	1 (1%) [1]	2 (1%) [2]	
Required or prolonged hospitalisation	5 (5%) [5]	4 (4%) [4]	9 (4%) [9]	
Other important medical condition	0	1 (1%) [1]	1 (<1%) [1]	
Relationship to trial drug (% of SAEs)				
Unlikely	2 (40%)	2 (40%)	4 (40%)	
Not related	3 (60%)	3 (60%)	6 (60%)	
<b>Severe AEs</b>	<b>9 (9%) [16]</b>	<b>5 (5%) [5]</b>	<b>14 (7%) [21]</b>	<b>p=0.28</b>
Relationship to trial drug (% of severe AEs)				
Definitely	8 (50%)	0	8 (38%)	
Probably	2 (13%)	2 (40%)	4 (19%)	
Possibly	3 (19%)	0	3 (14%)	
Unlikely	0	1 (20%)	1 (5%)	
Not related	3 (19%)	2 (40%)	5 (24%)	
<b>AEs probably/definitely related to first-line drugs</b>	<b>3 (3%) [3]</b>	<b>1 (1%) [1]</b>	<b>4 (2%) [4]</b>	<b>p=0.37</b>
<b>AEs probably/definitely related to retreatment drugs</b>	<b>3 (3%) [7]</b>	<b>1 (1%) [1]</b>	<b>4 (2%) [8]</b>	<b>p=0.37</b>
<b>First-line drug changes due to AEs</b>	<b>3 (3%) [3]</b>	<b>1 (1%) [1]</b>	<b>4 (2%) [4]</b>	<b>p=0.37</b>
<b>Retreatment drug changes due to AEs</b>	<b>6 (6%) [11]</b>	<b>1 (1%) [1]</b>	<b>7 (3%) [12]</b>	<b>p=0.06</b>
<b>Grade 3/4 anaemia</b>	<b>3(3%) [3]</b>	<b>0</b>	<b>3 (1%) [3]</b>	<b>p=0.12</b>

\*p-values calculated using chi-square tests or Fishers exact test when numbers are small.

Note: no. of patients (% of patients) [no. of events]. Tables include data for both first-line and retreatment phases. For SAEs, HR=0.77 (0.21, 2.80) p=0.69. For severe (grade 3/4 AEs), HR=1.74 (0.58, 5.24) p=0.33.

**Table 7. Details of adverse events.**

Event	Variable, ribavirin	Variable, no ribavirin	Fixed, ribavirin	Fixed, no ribavirin	Total Events
<b>SAEs</b>					
Accidental drug overdose*	1	0	0	0	1
Acute appendicitis	0	0	0	1	1
Adenocarcinoma in lower third of oesophagus*	0	0	0	1	1
Burn to foot - degree unknown	1	0	0	0	1
Liver abscess	1	0	0	0	1
Lower respiratory tract infection - pneumonia	1	0	0	0	1
Musculoskeletal pain in chest radiating to left arm	0	0	0	1	1
Pericarditis	1	0	0	0	1
R epididymo-orchitis	0	0	0	1	1
Urinary sepsis	0	0	0	1	1
<b>Severe AEs</b>					
Abscess leg	0	0	0	0	1
Alcohol intoxication acute	0	0	0	1	1
Anaemia	2	0	0	0	2
Cellulitis of leg	0	1	1	0	2
Concentration loss	1	0	0	0	1
Haemoglobin low	1	0	0	0	1
Hyperbilirubinemia	0	1	0	0	1
Inguinal hernia	1	0	0	0	1
Insomnia	3	0	0	0	3
Jaundice	0	0	0	1	1
Lethargic	1	0	0	0	1
Low mood	1	0	0	0	1
Pyelonephritis	0	0	1	0	1
Sores mouth	1	0	0	0	1
Suicidal ideation	1	0	0	0	1
Syncope	0	0	0	1	1
Tinnitus	1	0	0	0	1
<b>AEs probably/definitely related to trial drugs</b>					
Anaemia	2	0	0	0	2
Concentration loss	1	0	0	0	1
Haemoglobin low	1	0	0	0	1
Hyperbilirubinemia	0	1	0	0	1
Insomnia	3	0	0	0	3
Jaundice	0	0	0	1	1

Event	Variable, ribavirin	Variable, no ribavirin	Fixed, ribavirin	Fixed, no ribavirin	Total Events
Lethargic	1	0	0	0	1
Low mood	1	0	0	0	1
Syncope	0	0	0	1	1
Tinnitus	1	0	0	0	1
<b>Drug changes due to AEs</b>					
Anaemia	3	3	0	0	6
Concentration loss	1	0	0	0	1
Haemoglobin low	1	0	1	0	2
Hair loss	0	0	1	0	1
Hyperbilirubinemia	0	1	0	0	1
Insomnia	1	0	0	0	1
Lethargic	1	0	0	0	1
Low mood	1	0	0	0	1
Mouth ulcer	1	0	0	0	1
Sores mouth	1	0	0	0	1

\*Life-threatening events

**Table 8. Summary of adverse events by ribavirin randomisation.**

	With ribavirin	Without ribavirin	Total	p-value*
Number randomised	N=100	N=102	N=202	
Median weeks follow-up (IQR)	32.1 (30.4, 50.4)	32.1 (31.9, 49.0)	32.1 (31.2, 50.4)	
<b>SAEs</b>	<b>5 (5%) [5]</b>	<b>5 (5%) [5]</b>	<b>10 (5%) [10]</b>	<b>p=1.00</b>
SAE criteria				
Life-threatening	1 (1%) [1]	1 (1%) [1]	2 (1%) [2]	
Required or prolonged hospitalisation	5 (5%) [5]	4 (4%) [4]	9 (4%) [9]	
Other important medical condition	0	1 (1%) [1]	1 (<1%) [1]	
Relationship to ribavirin (% of SAEs)				
Unlikely	2 (40%)	2 (40%)	4 (40%)	
Not related	3 (60%)	3 (60%)	6 (60%)	
<b>Severe AEs</b>	<b>9 (9%) [15]</b>	<b>5 (5%) [6]</b>	<b>14 (7%) [21]</b>	<b>p=0.28</b>
Relationship to trial drug (% of severe AEs)				
Definitely	8 (53%)	0	8 (38%)	
Probably	1 (7%)	3 (50%)	4 (19%)	
Possibly	3 (20%)	0	3 (14%)	
Unlikely	1 (7%)	0	1 (5%)	



	With ribavirin	Without ribavirin	Total	p-value*
Not related	2 (13%)	3 (50%)	5 (24%)	
<b>AEs probably/definitely related to first line drugs</b>	<b>3 (3%) [3]</b>	<b>1 (1%) [1]</b>	<b>4 (2%) [4]</b>	<b>p=0.37</b>
<b>AEs probably/definitely related to retreatment drugs</b>	<b>2 (2%) [6]</b>	<b>2 (2%) [2]</b>	<b>4 (2%) [8]</b>	<b>p=1.00</b>
<b>First line drug changes due to AEs</b>	<b>4 (4%) [4]</b>	<b>0</b>	<b>4 (2%) [4]</b>	<b>p=0.06</b>
<b>Retreatment drug changes due to AEs</b>	<b>4 (4%) [8]</b>	<b>3 (3%) [4]</b>	<b>7 (3%) [12]</b>	<b>p=0.72</b>
<b>Grade 3/4 anaemia</b>	<b>3(3%) [3]</b>	<b>0</b>	<b>3 (1%) [3]</b>	<b>p=0.12</b>

\*p-values calculated using chi-square tests or Fishers exact test when numbers are small.

Note: no. of patients (% of patients) [no. of events]. Tables include data for both first-line and retreatment phases. For SAEs, HR=1.05 (95% CI 0.30, 3.63) p=0.94. For severe (grade 3/4 AEs), HR=1.92 (0.64, 5.72) p=0.59.

for DAA therapy<sup>24,25</sup>. Our findings suggest, for the first time, that very early responses to treatment (undetectable at day-3, or even day-7) may be helpful in predicting success of shortened treatment courses. Whilst not widely applicable, in specific supervised clinical settings (including in-patients, prisoners or directly observed daily therapy in the community) such an approach may help guide management and deserves further confirmation in prospective studies<sup>25-27</sup>.

This trial was designed to test treatment strategies, rather than specific regimens. Almost all recruitment happened when ombitasvir, paritaprevir, dasabuvir and ritonavir (Viekirax, Abbvie) was the preferred first-line treatment in the UK National Health Service (NHS). This combination remains a recommended NHS option, part of the WHO Essential Medicines List and is used in a number of countries. However, its use has been superseded by pangenotypic options in many settings and the extent to which these findings can be generalised to other combinations with broader genotype coverage is unknown. Given the similar declines in HCV VL between this and other DAA combinations (Figure 12), it seems plausible that the relationship between treatment duration and SVR12 is similar for other DAAs combinations approved for 12 weeks for patients with mild disease.

The trial required a population able to adhere to a schedule with significantly more visits than standard of care. Non-attendance was low and self-reported adherence reasonably high (Figure 5), despite one-third participants actively using recreational drugs. Following expanded access to DAA therapy, trial recruitment completed short of its original target when there were very few patients in need of treatment able to adhere to the follow-up schedule. However, higher than anticipated success of retreatment (predicted to be 85%, actually 100%) and lower than expected loss to follow-up meant that the trial was able to demonstrate non-inferiority according to its pre-specified margin, providing confidence that either strategy would result in an overall SVR12 rate of at least 96% (higher than originally specified).

The treatment of individuals who are unlikely to complete recommended treatment courses is crucial for elimination

strategies. Our findings suggest that ultrashort-courses of treatment can cure a significant proportion of patients with mild liver disease, without compromising retreatment in those not cured. Additional ribavirin in those unlikely to complete a course of treatment may be helpful to prevent the emergence of resistant virus.

## Data availability

### Underlying data

Figshare: STOP-HCV-1 trial data. <https://doi.org/10.6084/m9.figshare.14141411.v1><sup>18</sup>

This project contains the following underlying data:

- figsharedata.csv (Raw dataset containing baseline demographics, outcomes and VL results)

### Extended data

Figshare: STOP-HCV-1 supplementary material. <https://doi.org/10.6084/m9.figshare.14229212.v1><sup>17</sup>

This project contains the following extended data:

- STOP-HCV-1 supplementary material.docx (Supplementary methods and results)

### Reporting guidelines

Figshare: CONSORT checklist for 'Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C'. <https://doi.org/10.6084/m9.figshare.14216063.v1><sup>14</sup>

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

### Authors contributions

GC was the chief investigator. The trial was conceived and designed by GC, ASW, EB, SLP. The trial was managed by GC, ASW, SLP, FH, ED. The site principal investigators, responsible for participant recruitment and data collection, were RG, SV, GC, SR,JC,SB,AA,SB,MN, CC, BS,MW,DF,SM.

Statistical analysis was performed by LMc. Sequencing and bioinformatic analyses were performed by DN, DS, AA. The first draft was written by GC and ASW with review and comment from all authors.

## Acknowledgements

We thank all the participants and staff from all the centres participating in the STOP-HCV-1 trial (listed in supplementary material) and NHS England specialist commissioning. We thank the Trial Steering Committee (Professor Ian Weller (Chair), Dr Patrick Ingiliz, Dr Colette Smith, and Mr Robert James (Public and Patient representative)) and the Data Monitoring Committee (Professor David Laloo (Chair), Professor Tim Peto

and Professor Katherine Fielding). An earlier version of this manuscript is available at MedRxiv (<https://doi.org/10.1101/2021.01.22.21250208>)

## Role of the funding source

The funder had no role in the trial design, in the collection, analysis, and interpretation of data, writing of the report and in the decision to submit the paper for publication. First-line and second-line therapies, including ribavirin, were provided by the National Health Services within England, Wales and Scotland at no cost to participants. No company was involved in the design of the trial or provision of drugs.

## References

- WHO: **Global Health Sector Strategy on Viral Hepatitis**. Geneva: World Health Organization, 2016.  
[Reference Source](#)
- AASLD-IDS: **Hepatitis C Guidance 2018 Update: AASLD-IDS Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection**. *Clin Infect Dis*. 2018; **67**(10): 1477–1492.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- WHO: **Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection**. Geneva, Switzerland, 2018.  
[Reference Source](#)
- Younossi ZM, Stepanova M, Henry L, *et al.*: **Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens**. *Medicine (Baltimore)*. 2016; **95**(28): e4151.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Petersen T, Townsend K, Gordon LA, *et al.*: **High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study**. *Hepatol Int*. 2016; **10**(2): 310–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Martinello M, Matthews GV: **Management of acute HCV in the era of direct-acting antivirals: implications for elimination**. *Lancet Gastroenterol Hepatol*. 2019; **4**(4): 256–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- El Sherif O, Afhdal N, Curry M: **No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection**. *J Viral Hepat*. 2017; **24**(10): 808–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jones CR, Flower BF, Barber E, *et al.*: **Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis**. *Wellcome Open Res*. 2019; **4**: 132.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gilead Inc: **Harvoni US Full prescribing Information**. 2017. Accessed 12th February 2021.  
[Reference Source](#)
- Welzel TM, Asselah T, Dumas EO, *et al.*: **Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial**. *Lancet Gastroenterol Hepatol*. 2017; **2**(7): 494–500.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- EASL: **EASL Recommendations on Treatment of Hepatitis C 2018**. *J Hepatol*. 2018; **69**(2): 461–511.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Feld JJ, Jacobson IM, Sulkowski MS, *et al.*: **Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection**. *Liver Int*. 2017; **37**(1): 5–18.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nitta Y, Kawabe N, Hashimoto S, *et al.*: **Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C**. *Hepatol Res*. 2009; **39**(7): 675–84.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- McCabe L: **STOP-HCV-1 CONSORT checklist**. *figshare*. Figure. 2021.  
<http://www.doi.org/10.6084/m9.figshare.14216063.v1>
- NIAID: **DAIDS Adverse Event Grading Tables**. (Accessed 1st March 2021).  
[Reference Source](#)
- Thomson E, Ip CL, Badhan A, *et al.*: **Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes**. *J Clin Microbiol*. 2016; **54**(10): 2470–84.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- McCabe L: **STOP-HCV-1 supplementary material**. *figshare*. Dataset. 2021.  
<http://www.doi.org/10.6084/m9.figshare.14229212.v1>
- McCabe L: **STOP-HCV-1 trial data**. *figshare*. Dataset. 2021.  
<http://www.doi.org/10.6084/m9.figshare.14141411.v1>
- Kowdley KV, Lawitz E, Poordad F, *et al.*: **Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1**. *N Engl J Med*. 2014; **370**(3): 222–32.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gilead Inc: **Harvoni 90mg/ 400mg film-coated tablets SmPC**. 2019.  
[Reference Source](#)
- Madsen LW, Ovrehus A, Gerstoft J, *et al.*: **4 week treatment for hepatitis C - a randomized controlled trial (4RIBC)**. EASL. Vienna; 2019.  
[Reference Source](#)
- Galli A, Mens H, Gottwein JM, *et al.*: **Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model**. *Sci Rep*. 2018; **8**(1): 4619.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Di Martino V, Richou C, Cervoni JP, *et al.*: **Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future**. *Hepatology*. 2011; **54**(3): 789–800.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yakoot M, Abdo AM, Abdel-Rehim S, *et al.*: **Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial**. *EBioMedicine*. 2017; **21**: 182–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lau G, Benhamou Y, Chen G, *et al.*: **Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study**. *Lancet Gastroenterol Hepatol*. 2016; **1**(2): 97–104.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dahari H, Canini L, Graw F, *et al.*: **HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir**. *J Hepatol*. 2016; **64**(6): 1232–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fawsitt CG, Vickerman P, Cooke G, *et al.*: **A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus**. *Value Health*. 2019; **22**(6): 693–703.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)